Seminars in Hematology
Volume 47, Issue 2 , Pages 199-210, April 2010

CD20-Targeted Therapy: The Next Generation of Antibodies

  • Tom van Meerten

      Affiliations

    • Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • Anton Hagenbeek

      Affiliations

    • Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationAddress correspondence to Anton Hagenbeek, MD, PhD, Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 A.H. is member of the International Roche Advisory Board on Rituximab.

 Part of this paper was published in the Netherlands Journal of Medicine (2009 Jul-Aug;67(7):251-9). Approved by Neth J Med, M. Levi, Editor-in-Chief.

PII: S0037-1963(10)00008-9

doi:10.1053/j.seminhematol.2010.01.007

Seminars in Hematology
Volume 47, Issue 2 , Pages 199-210, April 2010

Article Tools

* Image Usage & Resolution